Spinout Active LTD

Company profile

Prokarium Limited

Home - Prokarium

Applications

CRN
06300883
Founded
2007
Age
19

Overview

Browse spinouts
Legal name
PROKARIUM LIMITED
Region
London
Registered address
LONDON BIOSCIENCE INNOVATION CENTRE
2 ROYAL COLLEGE STREET
LONDON
NW1 0NH
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Prokarium Limited
CRN 06300883
2
Direct and ultimate controller Active LTD
Prokarium Holdings Ltd
CRN 08933971

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

17 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

03 Jul
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

27 Aug
2024

Change Person Director Company With Change Date

Officers

CH01 | Transaction MzQzMzQ3OTA2OGFkaXF6a2N4

Published 27 Aug 2024 14:45

03 Jul
2007

Incorporated

Inception

Company registered at Companies House

Spinout profile

1 entry

Company description

Spin-out company developing vaccines

Project impact

company based on live attenuated vaccines

Prokarium
2011

Public funding

9 awards
First funded
2013
Funded years
2013, 2015, 2016, 2023, 2024
Age at first award
5 years

Projects

2024 Collaborative R&D Lead participant

Next generation living cures for cancer immunotherapy

1 Aug 2024 to 31 Jul 2025

Awarded
£317,615
Total cost £453,735

Cancer occurs when cells in the body accumulate genetic mutations that prompt them to grow uncontrollably, affecting normal body functions and potentially leading to death. Acquiring such mutations, and therefore developing a cancer, is more probable as we age. It is estimated that 1 in 2 people will experience cancer in their lifetime. Most standard canc...

2024 Collaborative R&D Lead participant

Development of a comprehensive microbial immunotherapy platform with immuno-transcriptomic monitoring for treatment of bladder cancer (DOCMI-BC)

1 Jan 2024 to 31 Dec 2025

Awarded
£200,490
Total cost £286,414

Bladder Cancer (BC) affects more than 550,000 people globally every year. With the highest recurrence rate of any known cancer (80%), it is one of the most expensive for the NHS to treat, costing £65M pa (CRUK). Current immunotherapy treatments based on the weakened strain of _Mycobacterium bovis_ (BCG) present a significant challenge, with substantial im...

2023 Collaborative R&D Lead participant

Intracellular bacterial delivery of therapeutic proteins for treatment of cancer

1 Aug 2023 to 31 Jul 2024

Awarded
£300,586
Total cost £429,409

Cancer occurs when cells in the body accumulate genetic mutations that prompt them to grow uncontrollably, affecting normal body functions and potentially leading to death. Acquiring such mutations, and therefore developing a cancer, is more probable as we age. It is estimated that 1 in 2 people will experience cancer in their lifetime. Most standard canc...

2016 Collaborative R&D Lead participant

Newton Fund - Development of an oral, thermostable enteric fever vaccine: saving lives and supporting tourism in Mexico

1 Nov 2016 to 31 Mar 2019

Awarded
£374,331
Total cost £534,759

Enteric fever is caused by two types of bacteria: Salmonella Typhi (typhoid) and Salmonella Paratyphi (paratyphoid), contracted from contaminated food or water. Although there are vaccines to prevent typhoid, there is no vaccine for paratyphoid which is a growing problem globally. With nearly 27 million global cases of enteric fever each year, Entervax™, ...

2016 Small Business Research Initiative Lead participant

Rapid, simple manufacture and clinical evaluation of an oral plague vaccine

1 Oct 2016 to 31 Dec 2019

Awarded
£1,035,557
Total cost £1,035,557

As recent disease outbreaks show, the world needs to be faster and better at developing, manufacturing, testing and distributing vaccines. Prokarium, a UK-based vaccine development company focusing on oral vaccines, can move from bench to clinic 6-12 months faster compared to most injectable vaccines, use the same manufacturing process to produce a wide r...

2016 Small Business Research Initiative Lead participant

An affordable, oral vaccine against mosquito- and sexually-transmitted Zika virus

1 Oct 2016 to 30 Sep 2017

Awarded
£274,823
Total cost £274,823

In February 2016 the WHO declared the Zika virus (ZIKV) to be a “Public Health Emergency of International Concern”. Experts now believe ZIKV is linked to a broad set of complications in pregnancy, including miscarriage, stillbirth, premature birth and eye problems with 29% of scans showing abnormalities in babies in the womb, including growth restrictions...

2016 Feasibility Studies

A novel prophylactic vaccine and delivery platform to prevent Clostridium difficile infections

1 May 2016 to 31 Oct 2017

Awarded
£33,982
Total cost £48,546

C. difficile infection (CDI) causes severe diarrhoea in hospital patients after treatment with broad-spectrumantibiotics. CDI can be successfully treated with specific antibiotics, but infection and diarrhoea re-occurs in upto 3 out of 10 patients and on average 2 of these will die. A vaccine could prevent CDI but none is currentlyavailable. The vaccines ...

2015 Feasibility Studies Lead participant

Breaking the cold chain for oral recombinant vaccines

1 Apr 2015 to 30 Jun 2016

Awarded
£29,427
Total cost £64,235

New vaccines are made from proteins that have to be injected using a needle. The process of making these proteins is very expensive and different for each vaccine. They cannot be put into tablets because they would be digested in the gut, and they need to be refrigerated and transported around developing countries via a distribution network called the col...

2013 Feasibility Studies Lead participant

Engineering immune-cell-targeting bacteria to express vaccines from within the body

1 Apr 2013 to 30 Sep 2014

Awarded
£238,803
Total cost £318,404

Prokarium Ltd of Keele, Staffordshire, has invented Vaxonella, a synthetic biology platform that promises to eliminate the need for needles for many vaccines. This is not only convenient for UK travellers going abroad, but will be essential in preventing diseases in rural areas where people do not have access to medical professionals. Vaxonella is based o...

Product types

Collaborative R&D Feasibility Studies Small Business Research Initiative